51 related articles for article (PubMed ID: 38745113)
1. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma.
Lin ZP; Hu XL; Chen D; Huang DB; Zou XG; Zhong H; Xu SX; Chen Y; Li XQ; Zhang J
World J Gastroenterol; 2024 May; 30(17):2321-2331. PubMed ID: 38813052
[TBL] [Abstract][Full Text] [Related]
3. Association of serum AFP trajectories and hepatocellular carcinoma outcomes after hepatic arterial infusion chemotherapy: A longitudinal, multicenter study.
An C; Wei R; Yao W; Han W; Li W; Shi G; Wu P
Cancer Med; 2024 Jun; 13(11):e7319. PubMed ID: 38819606
[TBL] [Abstract][Full Text] [Related]
4. A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy.
Zheng Z; Mei J; Guan R; Zhang J; Xiong X; Gan J; Li S; Guo R
Cancer Immunol Immunother; 2024 Jun; 73(8):158. PubMed ID: 38834790
[TBL] [Abstract][Full Text] [Related]
5. Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review.
Zhu S; Yu Y; Yang M; Liu X; Lai M; Zhong J; Zhao X; Lu L; Liu Y
Expert Rev Anticancer Ther; 2024 Jun; 24(6):423-434. PubMed ID: 38651280
[TBL] [Abstract][Full Text] [Related]
6. Hepatic Arterial Infusion Chemotherapy for Unresectable HCC: Ready for Primetime?
Yu Q; Ahmed O
Acad Radiol; 2024 Mar; 31(3):844-845. PubMed ID: 38365493
[No Abstract] [Full Text] [Related]
7. Downstaging strategies for unresectable hepatocellular carcinoma.
Karachaliou GS; Dimitrokallis N; Moris DP
World J Gastroenterol; 2024 May; 30(20):2731-2733. PubMed ID: 38855157
[TBL] [Abstract][Full Text] [Related]
8. Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial.
Lin YD; Wu GS; Rao MY; Liu YH; Han YW; Zhang J; Zhang JW
Sci Rep; 2024 May; 14(1):11486. PubMed ID: 38769368
[TBL] [Abstract][Full Text] [Related]
9. Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market.
Fellner C
P T; 2016 Aug; 41(8):523-5. PubMed ID: 27504069
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.
Xiao Y; Deng W; Luo L; Zhu G; Xie J; Liu Y; Wan R; Wen W; Hu Z; Shan R
BMC Cancer; 2024 May; 24(1):588. PubMed ID: 38745113
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
Xiao Y; Zhu G; Xie J; Luo L; Deng W; Lin L; Tao J; Hu Z; Shan R
J Hepatocell Carcinoma; 2023; 10():2049-2058. PubMed ID: 37965074
[TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.
Luo L; Xiao Y; Zhu G; Huang A; Song S; Wang T; Ge X; Xie J; Deng W; Hu Z; Wen W; Mei H; Wan R; Shan R
Front Oncol; 2022; 12():1004652. PubMed ID: 36237309
[TBL] [Abstract][Full Text] [Related]
13. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
Tomonari T; Tani J; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Asahiro M; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Masaki T; Takayama T
Cancer Med; 2023 Feb; 12(3):2646-2657. PubMed ID: 35964253
[TBL] [Abstract][Full Text] [Related]
14. Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
Ricke J; Schinner R; Seidensticker M; Gasbarrini A; van Delden OM; Amthauer H; Peynircioglu B; Bargellini I; Iezzi R; De Toni EN; Malfertheiner P; Pech M; Sangro B
J Hepatol; 2021 Dec; 75(6):1387-1396. PubMed ID: 34454995
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy
He MK; Liang RB; Zhao Y; Xu YJ; Chen HW; Zhou YM; Lai ZC; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Li QJ; Shi M
Ther Adv Med Oncol; 2021; 13():17588359211002720. PubMed ID: 33854567
[TBL] [Abstract][Full Text] [Related]
16. Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib
Mei J; Tang YH; Wei W; Shi M; Zheng L; Li SH; Guo RP
Front Oncol; 2021; 11():618206. PubMed ID: 33718175
[TBL] [Abstract][Full Text] [Related]
17. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma.
Llovet JM; Kelley RK; Villanueva A; Singal AG; Pikarsky E; Roayaie S; Lencioni R; Koike K; Zucman-Rossi J; Finn RS
Nat Rev Dis Primers; 2021 Jan; 7(1):6. PubMed ID: 33479224
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
